摘要
血源凝血因子Ⅷ是血液凝固过程中关键因子,为治疗甲型血友病的特效药,但存在价格昂贵、给药频率高和潜在的病毒污染风险等缺点;且由于血液制品来源有限,凝血因子Ⅷ类药物在国内供不应求。随着基因工程技术的发展,药用重组人凝血因子Ⅷ得以实现,在此基础上大量针对重组人凝血因子Ⅷ的结构改造研究不断涌现,部分产品已投放市场。文章主要对哺乳动物细胞表达的各类改构重组人凝血因子Ⅷ的原理和研究进展进行综述。由于存在提高蛋白质稳定性及延长药物半衰期等优势,结构改造将是重组人凝血因子Ⅷ类药物未来的技术发展方向。
As one of key factors in blood coagulation cascade,coagulation factor Ⅷ is used as a specific for Haemophilia A with a high price and a high administration frequency. Since traditional factor Ⅷ is prepared from human plasma,there' s potential risk of virus contamination,and for limitation of resource,factor Ⅷ is also hardly to be obtained in China. With development of genetic engineering techique,dozens of recombinant factor Ⅷ and recombinant factor Ⅷ with structure modification were expanded,some of them were developed as medicines and launched in market. The present review provides a research overview on mechanism and progress of the recombinant factor Ⅷ variants expressed in mammalian cells which aimed to be developed as medicines. With potential of enhanced stability and prolonged half-life,the modified recombinant factor Ⅷ would be trend in the future.
出处
《药物生物技术》
CAS
2015年第1期69-73,共5页
Pharmaceutical Biotechnology
